28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This program aimed to explore the use…
21 June 2022 – Race Oncology Limited (“Race”) is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or CS1) have been published in the…
08 June 2022 – Race Oncology Limited (“Race”) is pleased to announce it is expanding the FTO-targeted BISECT (RAC-006) clinical trial in extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS) to include five additional trial sites in Spain…
Phase 1b dose escalation stage of the Phase 1b/2 Zantrene study in AML has completed using a 4-day treatment of Zantrene in combination with fludarabine and clofarabine Encouraging clinical responses were observed in this very heavily pre-treated AML patient population…
Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML)…
Race Oncology CSO Dr Daniel Tillett talks to WIN Television News about Race Oncology’s research collaboration with the University of Wollongong.
6 April 2022 – Race Oncology Limited (“Race”) is pleased to announce it has receivedhuman ethics approval for its open label clinical trial of Zantrene® (bisantrenedihydrochloride) in patients with extramedullary Acute Myeloid Leukaemia (AML) or highrisk Myelodysplastic Syndrome (MDS). Before…
